Giredestrant vs Palazestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Giredestrant

Marketed by Roche

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04546009 · Phase 3 · active, not recruiting

This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.

Next expected readout: July 2027 · NCT03332797 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)

Result source: NCT04546009

Palazestrant

Developed by Olema Pharmaceuticals, Inc.

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Weak signal

NCT04505826 · Phase 1/2 · completed

The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.

Next expected readout: December 2027 · NCT05508906 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointGiredestrantPalazestrant
PFS, median—Trial running · NCT06065748—Trial running · NCT06016738
OS, median—Trial running · NCT06065748—Trial running · NCT06016738
ORR—Trial running · NCT06065748—Trial running · NCT06016738
Clinical benefit rate—Trial running · NCT06065748—Trial running · NCT06016738

PFS, median

Giredestrant
—Trial running · NCT06065748
Palazestrant
—Trial running · NCT06016738

OS, median

Giredestrant
—Trial running · NCT06065748
Palazestrant
—Trial running · NCT06016738

ORR

Giredestrant
—Trial running · NCT06065748
Palazestrant
—Trial running · NCT06016738

Clinical benefit rate

Giredestrant
—Trial running · NCT06065748
Palazestrant
—Trial running · NCT06016738
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Giredestrant: 3 of 4 rows · Palazestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGiredestrantPalazestrant
Dropout rate
8.7%a
NCT05659563 · Phase 2 · registry result, not featured evidence
—300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
0%300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
0%210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
0%150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
0%120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
0%90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
Discontinued due to AEs
—a
NCT05659563 · Phase 2 · registry result, not featured evidence
—300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Serious AEs
0%a
NCT05659563 · Phase 2 · registry result, not featured evidence
28.6%300 mg QDa
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
28.6%210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
40%150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
19.3%120 mg QD
NCT04505826 · Phase 1/2
57.1%120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
33.3%90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
12.1%60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Most frequent reported AEs
a
arthralgia 9.5%
hot flush 9.5%
fatigue 7.1%
NCT05659563 · Phase 2 · registry result, not featured evidence
300 mg QDa
nausea 85.7%
vomiting 71.4%
fatigue 57.1%
NCT04505826 · Phase 1/2
show 7 more results
210 mg QD
constipation 57.1%
nausea 57.1%
decreased appetite 42.9%
NCT04505826 · Phase 1/2
150 mg QD
nausea 80%
neutrophil count decreased 40%
vomiting 40%
NCT04505826 · Phase 1/2
120 mg QD
nausea 66.3%
fatigue 28.9%
vomiting 28.9%
NCT04505826 · Phase 1/2
120 mg QD
constipation 42.9%
hypokalaemia 42.9%
nausea 42.9%
NCT04505826 · Phase 1/2
90 mg QD
anxiety 33.3%
nausea 33.3%
photopsia 33.3%
NCT04505826 · Phase 1/2
60 mg QD
nausea 42.4%
fatigue 39.4%
headache 21.2%
NCT04505826 · Phase 1/2
30 mg QD
constipation 40%
diarrhoea 40%
fatigue 40%
NCT04505826 · Phase 1/2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Giredestrant

Ki67 -14.5% (n=40) vs -10% (n=44) Tamoxifen @ 2.14wk
absolute change · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence
Complete Cell Cycle Arrest 17.5% (n=40) vs 4.5% (n=44) Tamoxifen @ 2.14wk
absolute value · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence

Palazestrant

ORR 0% (n=4)300 mg QD
event count · % of participants
No placebo or comparator arm
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
show 7 more results
0% (n=4)*210 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=1)*150 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
6.5% (n=62)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 4 Participants as posted
0% (n=5)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=4)*90 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
7.1% (n=28)*60 mg QD
NCT04505826 · Phase 1/2 · converted to % from 2 Participants as posted
0% (n=5)*30 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · Palazestrant's landscape